Get Out the Clot Campaign Brings Together Leaders and Experts to Improve Patient Care for Venous Thromboembolism
The Get Out the Clot campaign has been launched by leading medical societies to improve patient care for venous thromboembolism (VTE). This collaborative initiative aims to identify gaps in care, standardize treatment, and expand access to innovative solutions for blood clot conditions. VTE affects up to 900,000 Americans annually, causing approximately 100,000 deaths and up to $10 billion in associated costs.
The campaign highlights the importance of standardized care paths and multidisciplinary approaches, such as VTE or PE response teams (PERTs), to improve diagnosis and treatment. It also emphasizes the need for awareness of newer treatments like computer-assisted vacuum thrombectomy and mechanical thrombectomy, which can quickly remove blood clots and improve patient outcomes.
The initiative is supported by organizations including the International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra, Inc. (NYSE: PEN), The PERT Consortium™, and the Society for Vascular Medicine (SVM).
La campagna Get Out the Clot è stata avviata da importanti società mediche per migliorare l'assistenza ai pazienti affetti da tromboembolismo venoso (VTE). Questa iniziativa collaborativa mira a identificare le lacune nell'assistenza, standardizzare i trattamenti e ampliare l'accesso a soluzioni innovative per le condizioni di formazione dei coaguli di sangue. Il VTE colpisce fino a 900.000 americani all'anno, causando circa 100.000 decessi e costi associati fino a 10 miliardi di dollari.
La campagna sottolinea l'importanza di percorsi di cura standardizzati e approcci multidisciplinari, come i team di risposta per VTE o PE (PERT), per migliorare la diagnosi e il trattamento. Inoltre, enfatizza la necessità di aumentare la consapevolezza su trattamenti più recenti come la trombectomia meccanica assistita da computer e la trombectomia meccanica, che possono rimuovere rapidamente i coaguli di sangue e migliorare i risultati per i pazienti.
L'iniziativa è sostenuta da organizzazioni tra cui la International Society on Thrombosis and Haemostasis (ISTH), la National Blood Clot Alliance (NBCA), la Penumbra, Inc. (NYSE: PEN), il PERT Consortium™ e la Society for Vascular Medicine (SVM).
La campaña Get Out the Clot ha sido lanzada por sociedades médicas líderes para mejorar la atención al paciente en relación con el tromboembolismo venoso (VTE). Esta iniciativa colaborativa tiene como objetivo identificar las brechas en la atención, estandarizar el tratamiento y ampliar el acceso a soluciones innovadoras para las condiciones de coágulos de sangre. El VTE afecta a hasta 900,000 estadounidenses anualmente, causando aproximadamente 100,000 muertes y hasta 10 mil millones de dólares en costos asociados.
La campaña destaca la importancia de los caminos de atención estandarizados y los enfoques multidisciplinarios, como los equipos de respuesta de VTE o PE (PERT), para mejorar el diagnóstico y el tratamiento. También enfatiza la necesidad de aumentar la conciencia sobre tratamientos más recientes, como la trombectomía mecánica asistida por computadora y la trombectomía mecánica, que pueden eliminar rápidamente los coágulos de sangre y mejorar los resultados de los pacientes.
La iniciativa cuenta con el apoyo de organizaciones como la International Society on Thrombosis and Haemostasis (ISTH), la National Blood Clot Alliance (NBCA), Penumbra, Inc. (NYSE: PEN), el PERT Consortium™ y la Society for Vascular Medicine (SVM).
Get Out the Clot 캠페인은 주요 의학 단체에 의해 Launch 되어 정맥 혈전 색전증(VTE) 환자의 치료를 개선하기 위해 기획되었습니다. 이 협력 이니셔티브는 치료의 격차를 찾아내고, 치료 표준화, 혈전 상태에 대한 혁신적인 솔루션에 대한 접근성을 확장하는 것을 목표로 합니다. VTE는 매년 최대 900,000명의 미국인에게 영향을 미치며, 약 100,000명의 사망과 최대 100억 달러의 관련 비용을 초래합니다.
이 캠페인은 진단 및 치료 개선을 위해 VTE 또는 PE 대응 팀(PERT)과 같은 표준화된 치료 경로와 다학제적 접근의 중요성을 강조합니다. 또한, 혈전을 신속하게 제거하고 환자 결과를 개선할 수 있는 컴퓨터 보조 진공 혈전절제술 및 기계적 혈전절제술과 같은 최신 치료법에 대한 인식 필요성을 강조합니다.
이 이니셔티브는 International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra, Inc. (NYSE: PEN), PERT Consortium™, Society for Vascular Medicine (SVM) 등 여러 조직의 지원을 받고 있습니다.
La campagne Get Out the Clot a été lancée par des sociétés médicales de premier plan pour améliorer les soins aux patients souffrant de thromboembolie veineuse (VTE). Cette initiative collaborative vise à identifier les lacunes dans les soins, à standardiser les traitements et à élargir l'accès à des solutions innovantes pour les troubles liés aux caillots sanguins. Le VTE touche jusqu'à 900 000 Américains chaque année, provoquant environ 100 000 décès et jusqu'à 10 milliards de dollars de coûts associés.
La campagne souligne l'importance des parcours de soins standardisés et des approches multidisciplinaires, telles que les équipes de réponse VTE ou PE (PERT), pour améliorer le diagnostic et le traitement. Elle met également l'accent sur la nécessité de sensibiliser aux traitements plus récents tels que la thrombectomie mécanique assistée par ordinateur et la thrombectomie mécanique, qui peuvent rapidement éliminer les caillots sanguins et améliorer les résultats pour les patients.
L'initiative est soutenue par des organisations telles que la International Society on Thrombosis and Haemostasis (ISTH), la National Blood Clot Alliance (NBCA), Penumbra, Inc. (NYSE: PEN), le PERT Consortium™ et la Society for Vascular Medicine (SVM).
Die Kampagne Get Out the Clot wurde von führenden medizinischen Gesellschaften ins Leben gerufen, um die Patientenversorgung bei venösen Thromboembolien (VTE) zu verbessern. Diese kollaborative Initiative hat das Ziel, Lücken in der Versorgung zu identifizieren, Behandlungen zu standardisieren und den Zugang zu innovativen Lösungen für Blutgerinnungszustände zu erweitern. VTE betrifft jährlich bis zu 900.000 Amerikaner, verursacht etwa 100.000 Todesfälle und bis zu 10 Milliarden Dollar an damit verbundenen Kosten.
Die Kampagne hebt die Bedeutung standardisierter Versorgungswege und multidisziplinärer Ansätze hervor, wie z.B. VTE- oder PE-Responder-Teams (PERT), um die Diagnose und Behandlung zu verbessern. Sie betont auch die Notwendigkeit, die Awareness neuerer Behandlungen wie der computerunterstützten Vakuumthrombektomie und der mechanischen Thrombektomie zu erhöhen, die Blutgerinnsel schnell entfernen und die Ergebnisse für die Patienten verbessern können.
Die Initiative wird von Organisationen unterstützt, zu denen die International Society on Thrombosis and Haemostasis (ISTH), die National Blood Clot Alliance (NBCA), Penumbra, Inc. (NYSE: PEN), das PERT Consortium™ und die Society for Vascular Medicine (SVM) gehören.
- Launch of a collaborative campaign to improve patient care for venous thromboembolism
- Support from major medical societies and organizations in the field
- Emphasis on standardizing care and expanding access to innovative treatments
- Potential for improved patient outcomes through multidisciplinary approaches and newer treatment options
- High prevalence of VTE affecting up to 900,000 Americans annually
- VTE leads to approximately 100,000 deaths per year
- Associated costs of VTE reaching up to $10 billion
- Existing gaps in care, including delays in diagnosis and misdiagnosis
Insights
The Get Out the Clot campaign represents a significant collaborative effort to address the critical issue of venous thromboembolism (VTE), which affects up to 900,000 Americans annually. This initiative is particularly impactful due to the high mortality rate and substantial economic burden associated with VTE, causing approximately 100,000 deaths and up to
The campaign's focus on standardizing care and promoting awareness of newer treatments like computer-assisted vacuum thrombectomy and mechanical thrombectomy is crucial. These advanced therapies have shown promise in reducing hospital stays, lowering bleeding risks and improving patient outcomes. However, the current landscape reveals concerning gaps in care, with studies indicating
For Penumbra (PEN), as a leading thrombectomy company, this campaign could potentially increase adoption of their technologies and expand their market presence. The collaboration with prominent medical societies lends credibility and may accelerate the acceptance of Penumbra's solutions in clinical practice. Investors should monitor how this initiative translates into increased product demand and potential revenue growth for PEN in the coming quarters.
Campaign is led by prominent medical societies to minimize discrepancies in treating blood clot conditions, such as in pulmonary embolism, where there are often delays in care (up to
"Every October, the ISTH leads the global charge with World Thrombosis Day, shining a spotlight on the critical yet often overlooked condition of thrombosis," said Pantep Angchaisuksiri, M.D., ISTH President. "This year's launch of the Get Out the Clot initiative is a call to action, rallying leaders in the field to combine their expertise and resources to significantly improve the lives of patients affected by blood clots. Together, we can drive change and save lives."
Venous thromboembolism (VTE), a medical condition characterized by the formation of blood clots in veins, effects up to 900,000 Americans annually leading to approximately 100,000 deaths and up to
"Given the incredibly high prevalence of VTE, it is critical that health systems create standardized care paths to help facilitate prompt diagnosis and implementation of appropriate treatment interventions," said Herb Aronow, M.D., MPH, Past President, Society for Vascular Medicine.
Recognizing a need to standardize the care approach for this patient population, VTE or PE response teams (PERTs) have begun to develop at institutions. These teams streamline care through a collaborative multidisciplinary approach by engaging experts with the knowledge of and access to a broad spectrum of resources and treatments, potentially improving patient outcomes.
"The Get Out the Clot campaign raises awareness of the critical need for a collaborative approach to care," said Rachel Rosovsky, M.D., MPH, Immediate Past President, The PERT Consortium™. "The PERT Consortium™ is proud to be part of this initiative and we are committed to working together to improve the care and outcomes for patients with blood clot conditions."
The current standards of care in the treatment of VTE include anticoagulation and clot-dissolving drugs such as thrombolytics. Studies have shown that newer treatments such as computer assisted vacuum thrombectomy and mechanical thrombectomy can remove blood clots quickly while also reducing hospital length of stay, lowering the risk of bleeding or invasive surgery, and improving patient outcomes. An objective of the Get Out the Clot campaign is to ensure that physicians are aware of and have access to these newer treatments.
"As a PE survivor who personally experienced delays in diagnosis and initially received the wrong treatment protocol, I understand how devastating these gaps in care can be," said Leslie Lake, volunteer president of the National Blood Clot Alliance. "The Get Out the Clot campaign is a crucial step toward changing that reality. By uniting experts and standardizing care, we can prevent the delays and misdiagnoses that cost lives, ensuring that more people receive the urgent, life-saving treatment they need."
"At Penumbra, our focus has always been to advance novel technologies to improve patient care worldwide," said James F. Benenati, M.D., FSIR, chief medical officer at Penumbra, the world's leading thrombectomy company. "By working together with these leading organizations in vascular care and advocacy, we hope to gain insights into the existing gaps in patient care and collaborate on solutions to improve patient outcomes."
Healthcare professionals should visit www.GetOutTheClot.com to learn more about the campaign and help raise awareness of VTE symptoms and treatment options.
About Get Out the Clot
Get Out the Clot is a collaborative educational initiative uniting experts in venous thromboembolism (VTE) care to help identify gaps in patient care related to blood clot conditions, including standardizing care and expanding access to the latest innovations to improve patient outcomes. The campaign is led by the International Society on Thrombosis and Haemostasis, National Blood Clot Alliance, Penumbra, The PERT Consortium™, and the Society for Vascular Medicine. The organizations involved with Get Out the Clot believe it is critical that health systems across
About the International Society on Thrombosis and Haemostasis (ISTH)
Founded in 1969, the ISTH is the leading global non-profit organization focused on advancing the science and clinical care of thrombosis and hemostasis. With a membership of over 7,000 clinicians, researchers, and educators from more than 110 countries, ISTH is dedicated to improving patient outcomes through cutting-edge research, education, and collaboration. Its world-renowned initiatives include educational and standardization programs, clinical and laboratory guidelines, research endeavors, congresses, and peer-reviewed publications. The Society also spearheads the annual World Thrombosis Day (WTD) campaign, observed on October 13. To learn more, visit www.isth.org or explore WTD at www.worldthrombosisday.org.
About National Blood Clot Alliance
Founded in 2003, the National Blood Clot Alliance (NBCA) is the premier not-for-profit organization in
About Penumbra
Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Its broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn and X.
About The PERT Consortium™
The purpose of The PERT Consortium™ is to serve the general public by undertaking activities to advance the status of PE care and promote research in the treatment of pulmonary embolism. Specifically, the Consortium's purpose is to:
Promote the adoption of the PERT model in healthcare institutions across
Expand the current body of scientific literature on the diagnosis and treatment of pulmonary embolism through the funding of scientific endeavors.
Educate the general public and healthcare professionals regarding pulmonary embolism diagnosis, treatment, and care.
By focusing solely on the entity of pulmonary embolism – its etiology, pathophysiology, prevention, management approach, outcomes of specific treatments, and follow-up pathways – it is the intention of the Consortium to increase awareness of treatment options available to patients with PE, to reduce its incidence worldwide, to improve health outcomes, and to positively influence the impact of this terrible disease.
About the Society for Vascular Medicine
The Society for Vascular Medicine is a professional organization that aims to improve the integration of vascular biological advances into medical practice and to maintain high standards of clinical vascular medicine. The Society is distinguished by its emphasis on clinical approaches to vascular disorders. Optimal vascular care is best accomplished by the collegial interaction of a community of vascular professionals, including individuals with expertise in vascular medicine, vascular surgery, interventional radiology, vascular nursing, vascular technology, and other disciplines. The Society recognizes the importance of individuals with diverse backgrounds in achieving ideal standards of research and clinical practice. The Society encourages these individuals to join the Society and to help accomplish its clinical and scientific mission.
Contact | |
Jennifer Heth | Parinaz Farzin |
Penumbra, Inc. | Merryman Communications |
510-995-9791 | 310-600-6746 |
___________________________ |
1 Hendriksen JM;Koster-van Ree M;Morgenstern MJ;Oudega R;Schutgens RE;Moons KG;Geersing GJ; (2017, March). Clinical characteristics associated with diagnostic delay of pulmonary embolism in primary care: A retrospective observational study. BMJ open. https://pubmed.ncbi.nlm.nih.gov/28279993/ |
2 Chun Shing Kwok, Chun Wai Wong, Saul Lovatt, Phyo K Myint, Yoon K Loke, Misdiagnosis of pulmonary embolism and missed pulmonary embolism: A systematic review of the literature, Health Sciences Review, Volume 3, 2022, 100022, ISSN 2772-6320, https://doi.org/10.1016/j.hsr.2022.100022. |
3 Centers for Disease Control and Prevention. (2023, June). Impact of Blood Clots on the United States Infographic. National Center on Birth Defects and Developmental Disabilities (NCBDDD). https://www.cdc.gov/blood-clots/toolkit/impact-of-blood-clots.html?CDC_AAref_Val=https://www.cdc.gov/ncbddd/dvt/infographic-impact.html. Accessed July 9, 2024. |
View original content to download multimedia:https://www.prnewswire.com/news-releases/get-out-the-clot-campaign-brings-together-leaders-and-experts-to-improve-patient-care-for-venous-thromboembolism-302272207.html
SOURCE Get Out the Clot
FAQ
What is the Get Out the Clot campaign for VTE treatment?
How many Americans are affected by VTE annually?
What organizations are involved in the Get Out the Clot campaign?
What are some newer treatments for VTE mentioned in the Get Out the Clot campaign?
When was the Get Out the Clot campaign launched in relation to World Thrombosis Day?
